1. Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab
- Author
-
Michael K. Yoon, Thomas N. Hwang, Aiyin Chen, Timothy J. McCulley, and Laura T Phan
- Subjects
Male ,Time Factors ,medicine.drug_class ,Biopsy ,Case Report ,Disease ,Monoclonal antibody ,Lymphoid hyperplasia ,Diagnosis, Differential ,Antibodies, Monoclonal, Murine-Derived ,Pseudolymphoma ,Maintenance therapy ,hemic and lymphatic diseases ,Benign Reactive Lymphoid Hyperplasia ,Long term management ,Orbital Diseases ,medicine ,Recurrent disease ,Humans ,Immunologic Factors ,Aged ,CD20 ,biology ,business.industry ,Systemic ,General Medicine ,Middle Aged ,Antigens, CD20 ,Magnetic Resonance Imaging ,Ophthalmology ,Immunology ,biology.protein ,Rituximab ,medicine.symptom ,business ,Follow-Up Studies ,medicine.drug - Abstract
Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.
- Published
- 2012